OncRef

Clinical Trial: NCT01715285

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Janssen Research & Development, LLC
Information Provided By:Janssen Research & Development, LLC
Last Update Posted:2025-02-04

Study Overview

Brief Summary

The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate plus low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).

Official Title

A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)

Conditions

Prostate Neoplasms

Intervention / Treatment

  • Drug: Abiraterone acetate
  • Drug: Prednisone
  • Other: Androgen deprivation therapy (ADT)
  • Drug: Abiraterone acetate Placebo
  • Drug: Prednisone Placebo

Other Study ID Numbers

  • CR100900
  • 212082PCR3011
  • 2012-002940-26
  • U1111-1135-7146

Start Date (Actual)

2013-02-12

Primary Completion Date (Actual)

2016-10-31

Study Completion Date (Actual)

2022-02-13

Enrollment (Actual)

1209

Study Type

Interventional

Phase

Phase 3